Research Grade Belatacept

Description: Belatacept (BS11220) is a research-grade recombinant antibody targeting CD80. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species:
Isotype: Fusion-[CTLA4(cytotoxicT-lymphocyte-associatedprotein4,CD152)]2-IGHG1Fc(Fragmentconstant)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: CD80,BB1,T-lymphocyteactivationantigenCD80,CD28LG,B7,CD28LG1,LAB7,ActivationB7-1antigen,CTLA-4counter-receptorB7.1,BU63,B70,CD28LG2,CTLA-4counter-receptorB7.2,ActivationB7-2antigen,T-lymphocyteactivationantigenCD86,CD86,FUN-1
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BMS-224818,LEA29Y,CAS:706808-37-9
Background: Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation.
Note: For research use only. Not suitable for clinical or therapeutic use.